Photo credit: Nucleate
Boston, MA — April 22nd, 2026 — Nucleate, the global nonprofit dedicated to empowering the next generation of biotech leaders, today announced the election of Chandra Ramanathan, Ph.D., M.B.A. as Executive Chair of its Board of Directors.
Chandra brings more than two decades of leadership experience across biopharma and academia, with a proven track record of translating cutting-edge science into impactful therapies and building high-value innovation ecosystems. His appointment marks a pivotal moment as Nucleate enters its next phase of growth — focused on strengthening the network effects that connect global talent, early-stage innovation, and opportunity.
Throughout his career, Chandra has operated at the intersection of science, strategy, and execution. As former Global Head of Innovation Hubs and Head of External Innovation at Danaher and Global Head of Open Innovation at Bayer, he led more than 60 partnerships spanning academia, biotech, and industry; generating over 70 preclinical programs and advancing multiple clinical assets. He has also played a key role in establishing innovation hubs, shaping early-stage portfolios, translating breakthrough technologies into viable product pipelines and served as global launch team leader for two drugs.
In addition to his industry leadership, Chandra has served on multiple boards and advisory groups, including MassBio, Johns Hopkins University, and McLean Hospital, and has been actively involved in advancing innovation strategy and entrepreneurship across the life sciences landscape.
“Chandra brings a rare combination of translational expertise, commercial insight, and ecosystem leadership,” said Oliver Dodd, Co-Founder and Executive Director at Nucleate. “His experience and vision will be instrumental as we continue to scale our platform and empower the next generation of founders tackling the toughest challenges in life sciences.”
As Executive Chair, Chandra will focus on three key priorities: strengthening Nucleate’s innovation engine, deepening engagement with academic and industry partners, and enhancing the connectivity of its global ecosystem. His leadership will further position Nucleate as a critical bridge between academic discovery and real-world patient impact — ensuring that founders can more effectively access the relationships, resources, and expertise needed to build successful ventures.
“Nucleate represents one of the most powerful platforms for unlocking early-stage scientific innovation and translating it into meaningful patient impact,” Chandra added, “I am excited to work with the Board and leadership team to strengthen our innovation model, deepen biopharma engagement, and further connect this global ecosystem — enabling entrepreneurs to succeed from day one.”
“Great talent and breakthrough innovation exist across the globe — but access to opportunity does not,” said Shruti Sridhar, Co-President at Nucleate. “Nucleate’s strength lies in connecting that talent to the right people, resources, and partners at the earliest stages. With Chandra’s leadership, we are uniquely positioned to strengthen these network effects globally — ensuring that all members of our community benefit from being a part of the Nucleate network.”
Chandra’s appointment builds on Nucleate’s continued momentum as the largest trainee-led global biotech accelerator. To date, the organization has supported more than 700 technology teams across 41 chapters globally, with alumni companies collectively raising over $700 million in follow-on capital and creating more than 900 jobs — driving innovation across therapeutics, diagnostics, and beyond.
With this leadership transition, Nucleate is poised to further accelerate its mission: training, connecting, and empowering the next generation of biotech leaders to tackle the world’s most pressing challenges in human and planetary health.
About Nucleate
Nucleate is a nonprofit organization dedicated to empowering the next generation of biotech leaders. With chapters spanning over 40 global regions and participation from hundreds of academic institutions, Nucleate builds communities that connect emerging talent with the resources, networks, and education needed to launch and scale biotech ventures. Through its programs, Nucleate is democratizing access to biotechnology innovation and enabling founders to develop solutions to the world’s most pressing health challenges. Learn more at www.nucleate.org.
This news was originally shared via Nucleate.
